title: Whole-abdomen radiation therapy in ovarian carcinoma: its role as a salvage therapeutic modality.
abstract: A significant proportion of patients with epithelial ovarian carcinoma eventually fail after initial responses to chemotherapy. Further treatment with chemotherapy consisting of either the same combination or second-line regimens has been ineffective in producing durable responses. Thus, between June 1983 and June 1987, thirty patients with epithelial ovarian carcinoma who failed one or more chemotherapeutic regimens were treated with whole-abdominopelvic-cavity radiation therapy. Prior to the radiation the amount of residual disease after debulking was noted to be microscopic in 16 patients and macroscopic in 14 patients. Radiation was delivered with an open-field technique that extended from the domes of the diaphragm to the obturator foramina. Doses of 2500 cGy were planned to the whole abdomen, with a boost of another 2500 cGy to the pelvic and or paraaortic nodes when indicated. Higher doses were delivered to the areas of gross disease in the pelvis. Only 2 patients were unable to complete the planned therapy. Another 26% of the patients required interruption of the therapy secondary to hematologic toxicity but eventually completed the treatment. With an overall median follow-up of 14 months, 56% of the patients remain alive. Two-year actuarial survival and recurrence-free survival rates are 47 and 32%, respectively. The survival and recurrence-free survival rates for the group with microscopic residual disease--61 and 33%, respectively--are better than those for the patients with macroscopic residual disease--36 and 18%. The abdominopelvic cavity was the first site of failure in all but one of the 17 patients who have failed. In spite of the higher doses, pelvic failure alone or as a component occurred in 54% of the patients. Small bowel obstruction necessitating surgical intervention as a complication of therapy was seen in 13% of the patients.
authors.affiliation: Department of Therapeutic Radiology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612.
authors.forename: S
authors.initials: S
authors.lastname: Reddy
authors.forename: W
authors.initials: W
authors.lastname: Hartsell
authors.forename: J
authors.initials: J
authors.lastname: Graham
authors.forename: E L
authors.initials: EL
authors.lastname: Yordan
authors.forename: M S
authors.initials: MS
authors.lastname: Lee
authors.forename: P
authors.initials: P
authors.lastname: Sarin
authors.forename: A K
authors.initials: AK
authors.lastname: Phillips
authors.forename: D
authors.initials: D
authors.lastname: McIntosh
authors.forename: G
authors.initials: G
authors.lastname: Wilbanks
mesh_terms: D000005:Abdomen / Q000528:radiation effects*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D012008:Recurrence